Clinical Trial Detail

NCT ID NCT02648711
Title Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cerulean Pharma Inc.
Indications

Advanced Solid Tumor

Therapies

CRLX101

Bevacizumab

Age Groups: adult

No variant requirements are available.